Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | SLC18A2 | Q05940 | 3/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.46 |
| ▸ | GRK2 | P25098 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17477235 | 1.00 | MAPT (0.60) | MAPTPKMSLC18A2HTR2ASLC6A3 | |
| SCHEMBL17485186 | 1.00 | MAPT (0.60) | MAPTPKMSLC18A2HTR2ASLC6A3 | |
| SCHEMBL17485211 | 1.00 | MAPT (0.60) | MAPTPKMSLC18A2HTR2ASLC6A3 | |
| SCHEMBL17486608 | 1.00 | MAPT (0.60) | MAPTPKMSLC18A2HTR2ASLC6A3 | |
| SCHEMBL7674961 | 1.00 | MAPT (0.60) | MAPTPKMSLC18A2HTR2ASLC6A3 | |
| SCHEMBL7674949 | 1.00 | MAPT (0.60) | MAPTPKMSLC18A2HTR2ASLC6A3 | |
| SCHEMBL17486605 | 0.90 | MAPT (0.63) | MAPTPKMSLC18A2SLC6A3MEN1 | |
| SCHEMBL17485268 | 0.90 | MAPT (0.63) | MAPTPKMSLC18A2SLC6A3MEN1 | |
| SCHEMBL17488515 | 0.89 | MAPT (0.59) | MAPTPKMSLC6A3CYP3A4 | |
| SCHEMBL17485168 | 0.87 | MAPT (0.60) | MAPTPKMSLC6A3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170298042-A1 | VMAT INHIBITORY COMPOUNDS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2017-10-19 | — | — | US | disclosed |
| US-9546151-B2 | VMAT inhibitory compounds | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160031852-A1 | VMAT INHIBITORY COMPOUNDS | WILMINGTON TRUST (LONDON) LIMITED, AS SECURITY AGENT (GB) | 2016-02-04 | — | — | US | disclosed |
| US-20020010155-A1 | Novel process | SMITHKLINE BEECHAM P.L.C. | 2002-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298042-A1 | VMAT INHIBITORY COMPOUNDS | SLC18A2, SLC18A3, SLC6A2 | MAPT 259/4885PKM 809/4885SLC18A2 1/4885 |
| US-20160031852-A1 | VMAT INHIBITORY COMPOUNDS | SLC18A2, SLC18A3, SLC6A2 | MAPT 259/4885PKM 809/4885SLC18A2 1/4885 |
| US-20020010155-A1 | Novel process | ADH1C, CBR1, ADH1A | MAPT 4765/4885PKM 1315/4885SLC18A2 3250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.